Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Losartan
Drug ID BADD_D01322
Description Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension.[L7423] Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough.[L7423] When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or [hydrochlorothiazide].[L7423] Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide.[L7423,L7426] Patients taking losartan should have their renal function and potassium levels monitored.[L7423] Losartan was granted FDA approval on 14 April 1995.[L7423]
Indications and Usage May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
Marketing Status Prescription; Discontinued
ATC Code C09CA01
DrugBank ID DB00678
KEGG ID D08146
MeSH ID D019808
PubChem ID 3961
TTD Drug ID D0DD0K
NDC Product Code Not Available
Synonyms Losartan | 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol | DuP-753 | DuP 753 | DuP753 | MK-954 | MK 954 | MK954 | Cozaar | Losartan Potassium | Potassium, Losartan | Losartan Monopotassium Salt | Monopotassium Salt, Losartan | Salt, Losartan Monopotassium
Chemical Information
Molecular Formula C22H23ClN6O
CAS Registry Number 114798-26-4
SMILES CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Capillary fragility increasedInterleukin-1 alphaP01583T1634026156105
Capillary fragility increasedInterleukin-10P29456Not Available26156105
Capillary fragility increasedC-C motif chemokine 2P14844Not Available26156105
Metabolic disorderCytochrome P450 2C9P11712T192449663807; 11434505; 9825828
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Ascites09.01.05.003; 07.07.01.001; 02.05.04.002--
Aspartate aminotransferase increased13.03.01.006--
Asthenia08.01.01.0010.001310%Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Atrial fibrillation02.03.03.002--
Atrioventricular block02.03.01.0020.000049%Not Available
Atrioventricular block second degree02.03.01.005--
Azotaemia20.01.01.0010.000049%Not Available
Back pain15.03.04.005--
Bladder cancer20.03.04.001; 16.08.01.001--Not Available
Blindness17.17.01.003; 06.02.02.001--Not Available
Blindness transient17.17.01.004; 06.02.02.0020.000049%Not Available
Blister12.01.06.002; 23.03.01.001--Not Available
Blood bilirubin increased13.03.01.008--
Blood creatinine abnormal13.13.01.0020.000097%Not Available
Blood creatinine increased13.13.01.0040.000315%
Blood glucose abnormal13.02.02.0080.000146%Not Available
Blood glucose decreased13.02.02.0010.000073%Not Available
Blood glucose increased13.02.02.002--Not Available
Blood iron abnormal13.11.01.0440.000170%Not Available
Blood iron decreased13.11.01.0060.000146%Not Available
Blood potassium decreased13.11.01.0100.000097%Not Available
Blood potassium increased13.11.01.0110.000243%Not Available
Blood pressure abnormal13.14.03.0010.000243%Not Available
Blood pressure decreased13.14.03.0020.000267%Not Available
Blood pressure fluctuation24.06.01.0020.000049%Not Available
Blood pressure increased13.14.03.0050.001407%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 19 Pages